Is TransMedics Group, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for TransMedics Group, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22.
In comparison to peers, TransMedics has a significantly higher P/E ratio than CONMED Corp. at 19.96 and Integer Holdings Corp. at 41.17, indicating a premium valuation relative to these companies. Additionally, the PEG ratio of 0.53 suggests that the stock may be undervalued in terms of its growth potential compared to its price. Although specific return data is not available, the absence of a return comparison with the S&P 500 does not detract from the overall assessment of fair valuation.